Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 ISIS 304801 in severe hypertriglyceridemia
NL-OMON43654Phase 3Active, not recruiting
- Sponsor
- Ionis Pharmaceuticals
- Start
- Jun 2015
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in hypertriglyceridemia comparing ISIS 304801 with Placebo (2 arms). Primary endpoint: Percent change from baseline in fasting triglycerides. Started Jun 2015; status: active, not recruiting.
02
Drugs
volanesorsen
03
Conditions
hypertriglyceridemia
Beyond the preview
Go deeper on NL-OMON43654.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON43654.